Literature DB >> 18359407

CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004.

Peter A McCullough1, Suying Li, Claudine T Jurkovitz, Lesley A Stevens, Changchun Wang, Allan J Collins, Shu-Cheng Chen, Keith C Norris, Samy I McFarlane, Bruce Johnson, Michael G Shlipak, Chamberlain I Obialo, Wendy Weinstock Brown, Joseph A Vassalotti, Adam T Whaley-Connell.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) is recognized as an independent cardiovascular disease risk state. The relationship between CKD and cardiovascular disease in volunteer and general populations has not been explored.
METHODS: The National Kidney Foundation Kidney Early Evaluation Program (KEEP) is a community-based health-screening program to raise kidney disease awareness and detect CKD for early disease intervention in individuals 18 years or older with diabetes, hypertension, or family history of kidney disease, diabetes, or hypertension. KEEP volunteers completed surveys and underwent blood pressure and laboratory testing. Estimated glomerular filtration rate (eGFR) was computed, and urine albumin-creatinine ratio (ACR) was measured. In KEEP, CKD was defined as eGFR less than 60 mL/min/1.73 m(2) or ACR of 30 mg/g or greater. Cardiovascular disease was defined as self-reported myocardial infarction or stroke. Data were compared with National Health and Nutrition Examination Survey (NHANES) 1999-2004 data for prevalence of cardiovascular disease risk factors and cardiovascular outcomes.
RESULTS: Of 69,244 KEEP participants, mean age was 53.4 +/- 15.7 years, 68.3% were women, 33.0% were African American, and 27.6% had diabetes. Of 17,061 NHANES participants, mean age was 45.1 +/- 0.27 years, 52% were women, 11.2% were African American, and 6.7% had diabetes. In KEEP, 26.8% had CKD, and in NHANES, 15.3%. ACR was the dominant positive screening test for younger age groups, and eGFR, for older age groups, for both populations. Prevalences of myocardial infarction or stroke were 16.5% in KEEP and 15.1% in NHANES (P < 0.001) and 7.8% in KEEP and 3.7% in NHANES (P < 0.001) for individuals with and without CKD, respectively. In adjusted analysis of both KEEP and NHANES data, CKD was associated with a significantly increased risk of prevalent myocardial infarction or stroke (odds ratio, 1.34; 95% confidence interval, 1.25 to 1.43; odds ratio, 1.37; 95% confidence interval, 1.10 to 1.70, respectively). In KEEP, short-term mortality was greater in individuals with CKD (1.52 versus 0.33 events/1,000 patient-years).
CONCLUSIONS: CKD is independently associated with myocardial infarction or stroke in participants in a voluntary screening program and a randomly selected survey population. Heightened concerns regarding risks in volunteers yielded greater cardiovascular disease prevalence in KEEP, which was associated with increased short-term mortality.

Entities:  

Mesh:

Year:  2008        PMID: 18359407     DOI: 10.1053/j.ajkd.2007.12.017

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  40 in total

1.  Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease.

Authors:  Dana V Rizk; Orlando Gutierrez; Emily B Levitan; William M McClellan; Monika Safford; Elsayed Z Soliman; David G Warnock; Paul Muntner
Journal:  Nephrol Dial Transplant       Date:  2011-12-13       Impact factor: 5.992

2.  Mitigating the cardiovascular risk of anemia in patients with type 2 diabetes and CKD: Does darbepoetin help? The TREAT Trial.

Authors:  Christi Hayes; Anis Alam; Julie Black-Peart; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2010-04       Impact factor: 4.810

Review 3.  Cardiovascular disease in chronic kidney disease: data from the Kidney Early Evaluation Program (KEEP).

Authors:  Peter A McCullough; Susan Steigerwalt; Kirit Tolia; Shu-Cheng Chen; Suying Li; Keith C Norris; Adam Whaley-Connell
Journal:  Curr Diab Rep       Date:  2011-02       Impact factor: 4.810

4.  Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.

Authors:  Darshika Chhabra; Anton I Skaro; Joseph R Leventhal; Pranav Dalal; Gaurav Shah; Edward Wang; Lorenzo Gallon
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 8.237

5.  Prevalence of baseline chronic kidney disease in 2,769 Chinese patients with renal cancer: nephron-sparing treatment is still underutilized.

Authors:  Kai-wei Yang; Geng-yan Xiong; Xue-song Li; Yuan Tang; Qi Tang; Cui-jian Zhang; Zhi-song He; Li-qun Zhou
Journal:  World J Urol       Date:  2014-08       Impact factor: 4.226

Review 6.  World Kidney Day 2011: protect your kidneys, save your heart.

Authors:  William G Couser; Miguel C Riella
Journal:  Pediatr Nephrol       Date:  2011-01-20       Impact factor: 3.714

7.  Trends in the levels of urine and serum creatinine: data from NHANES 2001-2014.

Authors:  Ram B Jain
Journal:  Environ Sci Pollut Res Int       Date:  2017-03-06       Impact factor: 4.223

8.  Cardiometabolic risk profile of rural South Indians undergoing coronary interventions.

Authors:  Manne Sriharibabu; Yalamanchali Himabindu; Zubair Kabir
Journal:  Heart Asia       Date:  2012-10-24

9.  Cystatin C, mortality risk and clinical triage in US adults: threshold values and hierarchical importance.

Authors:  Robert N Foley; Changchun Wang; Allan J Collins
Journal:  Nephrol Dial Transplant       Date:  2010-10-20       Impact factor: 5.992

10.  Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative.

Authors:  Claudio Ronco; Peter McCullough; Stefan D Anker; Inder Anand; Nadia Aspromonte; Sean M Bagshaw; Rinaldo Bellomo; Tomas Berl; Ilona Bobek; Dinna N Cruz; Luciano Daliento; Andrew Davenport; Mikko Haapio; Hans Hillege; Andrew A House; Nevin Katz; Alan Maisel; Sunil Mankad; Pierluigi Zanco; Alexandre Mebazaa; Alberto Palazzuoli; Federico Ronco; Andrew Shaw; Geoff Sheinfeld; Sachin Soni; Giorgio Vescovo; Nereo Zamperetti; Piotr Ponikowski
Journal:  Eur Heart J       Date:  2009-12-25       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.